妊娠期喹硫平与阿立哌唑的PBPK剂量调整研究
研究采用生理药代动力学(PBPK)模型预测妊娠期喹硫平、阿立哌唑及其活性代谢物去氢阿立哌唑的药代动力学。模型预测妊娠早、中、晚三期稳态AUC分别下降:喹硫平8.7%、35.0%、49.1%,阿立哌唑活性部分12.6%、38.8%、60.9%。结论建议妊娠后两期增加剂量,晚孕期喹硫平和阿立哌唑剂量至少分别为基线剂量的2.5倍和2倍。
要点
- 妊娠中晚期喹硫平和阿立哌唑血药浓度显著下降,需考虑剂量上调。
- 晚孕期建议喹硫平剂量至少为基线2.5倍,阿立哌唑至少2倍。
- 晚孕期喹硫平浓度多低于治疗范围下限100 ng/mL,阿立哌唑无法达到有效浓度150 ng/mL。
核心结论
- 根据PBPK预测,妊娠后两期应增加喹硫平和阿立哌唑剂量。
- 晚孕期建议喹硫平和阿立哌唑剂量至少分别为基线剂量的2.5倍和2倍。
研究设计与样本
- 采用自下而上与自上而下结合策略构建PBPK模型,预测妊娠三期稳态药代动力学。
- 模型通过拟合优度图和预测与观测药代参数比值验证。
主要发现
- 妊娠早、中、晚三期稳态AUC下降:喹硫平8.7%、35.0%、49.1%,阿立哌唑活性部分12.6%、38.8%、60.9%。
- 晚孕期喹硫平血药浓度大部分时间低于治疗范围下限100 ng/mL。
- 晚孕期阿立哌唑完全无法达到有效浓度150 ng/mL。
关键数值与推荐
- 喹硫平治疗范围下限为100 ng/mL,阿立哌唑有效浓度为150 ng/mL。
- 晚孕期喹硫平剂量至少为基线2.5倍,阿立哌唑至少为基线2倍。
临床怎么用
- 临床可参考PBPK预测,在妊娠中晚期考虑上调喹硫平和阿立哌唑剂量。
- 晚孕期应关注血药浓度监测,确保达到治疗范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Quetiapine and aripiprazole are currently prescribed for pregnant women to treat schizophrenia and bipolar disorder. A dramlatic decline in the plasma concentrations of these two drugs was observed if the doses remained fixed throughout pregnancy. This study aims to develop physiologically based pharmacokinetic (PBPK) models to predict the pharmacokinetics of quetiapine, aripiprazole, and the active aripiprazole metabolite dehydroaripiprazole during pregnancy. METHODS: We developed models using a combined 'bottom-up' and 'top-down' strategy. Models were verified by assessing goodness-of-fit plots and ratios of predicted-to-observed pharmacokinetic parameters. To extrapolate to pregnancy, we considered anatomical, physiological, and metabolic alterations. The in silico models were applied to predict steady-state pharmacokinetics in the three stages of pregnancy and to inform dose selection. RESULTS: We successfully constructed PBPK models that accurately predicted the pharmacokinetics of drugs in the adult population. Predictions suggested that the area under the concentration-time curve at steady state in the first, second, and third trimesters, respectively, decreased by 8.7%, 35.0%, and 49.1% for quetiapine and 12.6%, 38.8%, and 60.9% for the active moiety of aripiprazole. The third-trimester plasma concentrations of quetiapine were below the lower limit of the therapeutic range (100 ng/mL) for most of the time interval, and aripiprazole was entirely unable to reach its effective concentration (150 ng/mL). CONCLUSIONS: According to PBPK predictions, the doses should be increased in the latter two trimesters. We generally recommend that women during late pregnancy take at least 2.5- and 2-times their baseline doses of quetiapine and aripiprazole, respectively.
引用
- Zheng L, Tang S, Tang R, et al. Dose Adjustment of Quetiapine and Aripiprazole for Pregnant Women Using Physiologically Based Pharmacokinetic Modeling and Simulation. Clin Pharmacokinet. 2020. PMID: 33251573. doi:10.1007/s40262-020-00962-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。